$16.46
10.93% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US07373V1052
Symbol
BEAM
Sector
Industry

Beam Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Beam Therapeutics Inc Classifications & Recommendation:

Buy
83%
Hold
17%

Beam Therapeutics Inc Price Target

Target Price $48.06
Price $16.46
Potential
Number of Estimates 16
16 Analysts have issued a price target Beam Therapeutics Inc 2026 . The average Beam Therapeutics Inc target price is $48.06. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 15 Analysts recommend Beam Therapeutics Inc to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Beam Therapeutics Inc stock has an average upside potential 2026 of . Most analysts recommend the Beam Therapeutics Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 63.52 63.50
83.18% 0.03%
EBITDA Margin -619.71% -708.02%
1,395.95% 14.25%
Net Margin -603.00% -622.68%
1,483.38% 3.26%

16 Analysts have issued a sales forecast Beam Therapeutics Inc 2025 . The average Beam Therapeutics Inc sales estimate is

$63.5m
Unlock
. This is
0.03% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$110m 73.17%
Unlock
, the lowest is
$40.0m 37.03%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $63.5m 83.18%
2025
$63.5m 0.03%
Unlock
2026
$65.2m 2.75%
Unlock
2027
$86.0m 31.75%
Unlock
2028
$195m 126.66%
Unlock
2029
$536m 174.85%
Unlock

5 Analysts have issued an Beam Therapeutics Inc EBITDA forecast 2025. The average Beam Therapeutics Inc EBITDA estimate is

$-450m
Unlock
. This is
14.21% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-346m 12.03%
Unlock
, the lowest is
$-503m 27.71%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-394m 151.58%
2025
$-450m 14.21%
Unlock
2026
$-482m 7.12%
Unlock
2027
$-470m 2.51%
Unlock
2028
$-245m 47.84%
Unlock
2029
$-204m 16.90%
Unlock

EBITDA Margin

2024 -619.71% 1,395.95%
2025
-708.02% 14.25%
Unlock
2026
-738.14% 4.25%
Unlock
2027
-546.17% 26.01%
Unlock
2028
-125.69% 76.99%
Unlock
2029
-38.00% 69.77%
Unlock

17 Beam Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Beam Therapeutics Inc net profit estimate is

$-395m
Unlock
. This is
3.23% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-273m 28.60%
Unlock
, the lowest is
$-501m 30.79%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-383m 166.28%
2025
$-395m 3.23%
Unlock
2026
$-397m 0.37%
Unlock
2027
$-396m 0.27%
Unlock
2028
$-319m 19.29%
Unlock
2029
$-169m 47.02%
Unlock

Net Margin

2024 -603.00% 1,483.38%
2025
-622.68% 3.26%
Unlock
2026
-608.23% 2.32%
Unlock
2027
-460.41% 24.30%
Unlock
2028
-163.94% 64.39%
Unlock
2029
-31.60% 80.72%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.58 -4.73
166.28% 3.28%
P/E negative
EV/Sales 15.02

17 Analysts have issued a Beam Therapeutics Inc forecast for earnings per share. The average Beam Therapeutics Inc EPS is

$-4.73
Unlock
. This is
3.28% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-3.27 28.60%
Unlock
, the lowest is
$-5.99 30.79%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.58 166.28%
2025
$-4.73 3.28%
Unlock
2026
$-4.75 0.42%
Unlock
2027
$-4.73 0.42%
Unlock
2028
$-3.82 19.24%
Unlock
2029
$-2.02 47.12%
Unlock

P/E ratio

Current -3.60 79.20%
2025
-3.48 3.33%
Unlock
2026
-3.47 0.29%
Unlock
2027
-3.48 0.29%
Unlock
2028
-4.31 23.85%
Unlock
2029
-8.13 88.63%
Unlock

Based on analysts' sales estimates for 2025, the Beam Therapeutics Inc stock is valued at an EV/Sales of

15.02
Unlock
and an P/S ratio of
25.88
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 15.02 237.53%
2025
15.02 0.03%
Unlock
2026
14.62 2.68%
Unlock
2027
11.10 24.10%
Unlock
2028
4.90 55.88%
Unlock
2029
1.78 63.62%
Unlock

P/S ratio

Current 25.87 262.20%
2025
25.88 0.03%
Unlock
2026
25.19 2.68%
Unlock
2027
19.12 24.10%
Unlock
2028
8.43 55.88%
Unlock
2029
3.07 63.62%
Unlock

Current Beam Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
B of A Securities
Locked
Locked
Locked Mar 28 2025
Cantor Fitzgerald
Locked
Locked
Locked Mar 12 2025
Jones Trading
Locked
Locked
Locked Mar 10 2025
Scotiabank
Locked
Locked
Locked Mar 10 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 10 2025
Scotiabank
Locked
Locked
Locked Mar 03 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 28 2025
Analyst Rating Date
Locked
B of A Securities:
Locked
Locked
Mar 28 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Mar 12 2025
Locked
Jones Trading:
Locked
Locked
Mar 10 2025
Locked
Scotiabank:
Locked
Locked
Mar 10 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 10 2025
Locked
Scotiabank:
Locked
Locked
Mar 03 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 28 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today